Fifteen-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer

Hamdy, Freddie C., Donovan, Jenny L., Lane, J. Athene, Metcalfe, Chris, Davis, Michael, Turner, Emma L., Martin, Richard M., Young, Grace J., Walsh, Eleanor I., Bryant, Richard J., Bollina, Prasad, Doble, Andrew, Doherty, Alan, Gillatt, David, Gnanapragasam, Vincent, Hughes, Owen, Kockelbergh, Roger, Kynaston, Howard ORCID: https://orcid.org/0000-0003-1902-9930, Paul, Alan, Paez, Edgar, Powell, Philip, Rosario, Derek J., Rowe, Edward, Mason, Malcolm ORCID: https://orcid.org/0000-0003-1505-2869, Catto, James W.F., Peters, Tim J., Oxley, Jon, Williams, Naomi J., Staffurth, John ORCID: https://orcid.org/0000-0002-7834-3172 and Neal, David E. 2023. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine 388 , pp. 1547-1558. 10.1056/NEJMoa2214122

Preview

PDF - Published Version Download (701kB) | Preview

Abstract

BACKGROUND Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed in 2664 men. Of these men, 1643 were enrolled in a trial to evaluate the effectiveness of treatments, with 545 randomly assigned to receive active monitoring, 553 to undergo prostatectomy, and 545 to undergo radiotherapy. METHODS At a median follow-up of 15 years (range, 11 to 21), we compared the results in this population with respect to death from prostate cancer (the primary outcome) and death from any cause, metastases, disease progression, and initiation of long-term androgen-deprivation therapy (secondary outcomes). RESULTS Follow-up was complete for 1610 patients (98%). A risk-stratification analysis showed that more than one third of the men had intermediate or high-risk disease at diagnosis. Death from prostate cancer occurred in 45 men (2.7%): 17 (3.1%) in the active-monitoring group, 12 (2.2%) in the prostatectomy group, and 16 (2.9%) in the radiotherapy group (P=0.53 for the overall comparison). Death from any cause occurred in 356 men (21.7%), with similar numbers in all three groups. Metastases developed in 51 men (9.4%) in the active-monitoring group, in 26 (4.7%) in the prostatectomy group, and in 27 (5.0%) in the radiotherapy group. Long-term androgen-deprivation therapy was initiated in 69 men (12.7%), 40 (7.2%), and 42 (7.7%), respectively; clinical progression occurred in 141 men (25.9%), 58 (10.5%), and 60 (11.0%), respectively. In the active-monitoring group, 133 men (24.4%) were alive without any prostate cancer treatment at the end of follow-up. No differential effects on cancer-specific mortality were noted in relation to the baseline PSA level, tumor stage or grade, or risk-stratification score. No treatment complications were reported after the 10-year analysis. CONCLUSIONS After 15 years of follow-up, prostate cancer–specific mortality was low regardless of the treatment assigned. Thus, the choice of therapy involves weighing trade-offs between benefits and harms associated with treatments for localized prostate cancer. (Funded by the National Institute for Health and Care Research; ProtecT Current Controlled Trials number, ISRCTN20141297. opens in new tab; ClinicalTrials.gov number, NCT02044172. opens in new tab.)

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Massachusetts Medical Society
ISSN:	0028-4793
Date of First Compliant Deposit:	17 March 2023
Date of Acceptance:	11 March 2023
Last Modified:	12 Sep 2023 17:07
URI:	https://orca.cardiff.ac.uk/id/eprint/157779

Actions (repository staff only)

Edit Item